Janux Therapeutics Inc (JANX)

$13.70 +0.05 (0.37%)
Market Cap 821.02M
Revenue (ttm) 10.59M
Net Income (ttm) -68.99M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -651.46%
Debt to Equity Ratio 0.00
Volume 593,900
Avg Vol 1,755,636
Day's Range N/A - N/A
Shares Out 60.15M
Stochastic %K 73%
Beta 2.88
Analysts Strong Sell
Price Target $58.65

Company Profile

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, a...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 751 4493
Address:
10955 Vista Sorrento Parkway, Suite 200, San Diego, United States
forprofit12
forprofit12 Feb. 25 at 6:06 PM
$JANX when is ER? Website does not have anything under events.
1 · Reply
bc4
bc4 Feb. 25 at 3:03 PM
$JANX 1 more day to go. Partnership we have with bristol will deliver only good news tomorrow
0 · Reply
civickid75
civickid75 Feb. 24 at 7:15 PM
$JANX the squeeze, if it happens, will take this a lot higher. 13 days to cover. Let’s see if people will take notice.
0 · Reply
Harry900
Harry900 Feb. 24 at 2:55 PM
$JANX Down market, posts are so so fearful and now we’re firming. I’ve been wrong before, but I sense something’s up. I’m calling the basing complete here. Blue skys ahead. GLTA Harry
0 · Reply
metalcook
metalcook Feb. 24 at 2:51 PM
$VIR highest short % of the year. Ofcourse thsi will squeeze. +30% just adds the cash. Now add the value of Astellas as partner + viable drug + viable platform with 2 targets to go + Hep D franshise worth around 600mil$. $JANX at its peak was 2.5bl $ worth. That would equit to 20$ per share for $VIR
0 · Reply
metalcook
metalcook Feb. 23 at 11:29 PM
$VIR $JANX far exceeded expectations. I am not a fan of partnering such an asset. They should go for it alone
0 · Reply
UgoGreg
UgoGreg Feb. 21 at 4:19 PM
$JANX https://youtu.be/ygBN8MilTyc
0 · Reply
bohrsmodel
bohrsmodel Feb. 20 at 9:18 PM
$JANX $50 price target! https://finviz.com/news/315826/where-is-janux-therapeutics-janx-headed-according-to-analysts
0 · Reply
DanishViking92
DanishViking92 Feb. 20 at 8:45 PM
$JANX Maybe we will see a rebound on earnings release if they bring a positive update on the $50M payment they are waiting for.. should i buy or is it too risky? I mean it have been below $10 before.
0 · Reply
Milanfinest
Milanfinest Feb. 19 at 5:26 PM
$JANX so
0 · Reply
Latest News on JANX
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011

Feb 17, 2026, 7:00 AM EST - 8 days ago

Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011

Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer

Jan 26, 2026, 7:00 AM EST - 4 weeks ago

Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer

Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million

Jan 22, 2026, 2:02 PM EST - 4 weeks ago

Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million

BMY

Janux Therapeutics, Bristol Myers enter up to $850 million deal to develop cancer drug

Jan 22, 2026, 7:38 AM EST - 4 weeks ago

Janux Therapeutics, Bristol Myers enter up to $850 million deal to develop cancer drug

BMY

Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors

Jan 22, 2026, 7:00 AM EST - 4 weeks ago

Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors

Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study

Dec 23, 2025, 4:05 PM EST - 2 months ago

Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study

Janux Therapeutics Stock Hits 52-Week Low After Trial Update

Dec 2, 2025, 10:58 AM EST - 3 months ago

Janux Therapeutics Stock Hits 52-Week Low After Trial Update

Janux dives as gaps in prostate cancer study data worry investors

Dec 2, 2025, 10:50 AM EST - 3 months ago

Janux dives as gaps in prostate cancer study data worry investors

Signet Jewelers, Janux Therapeutics, BW LPG And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Dec 2, 2025, 8:41 AM EST - 3 months ago

Signet Jewelers, Janux Therapeutics, BW LPG And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

BWLP SIG

Janux Therapeutics Stock Craters After ‘Positive' Cancer Drug Trial Data. Why It's Down 41%.

Dec 2, 2025, 8:30 AM EST - 3 months ago

Janux Therapeutics Stock Craters After ‘Positive' Cancer Drug Trial Data. Why It's Down 41%.

Janux Therapeutics, Inc. (JANX) Shareholder/Analyst Call Transcript

Dec 1, 2025, 11:13 PM EST - 3 months ago

Janux Therapeutics, Inc. (JANX) Shareholder/Analyst Call Transcript

Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC

Dec 1, 2025, 4:05 PM EST - 3 months ago

Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC

Janux Therapeutics to Host Virtual Event Discussing Updated Phase 1a and Phase 1b Clinical Data for JANX007 in mCRPC

Nov 24, 2025, 8:00 AM EST - 3 months ago

Janux Therapeutics to Host Virtual Event Discussing Updated Phase 1a and Phase 1b Clinical Data for JANX007 in mCRPC

Janux Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

Nov 6, 2025, 4:01 PM EST - 3 months ago

Janux Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

Aug 7, 2025, 4:01 PM EDT - 7 months ago

Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

Janux Therapeutics Announces Clinical Milestone Achievement in TRACTr Collaboration With Merck

Aug 5, 2025, 4:05 PM EDT - 7 months ago

Janux Therapeutics Announces Clinical Milestone Achievement in TRACTr Collaboration With Merck

Janux: A High-Risk/High-Reward Bet On Oncology And Autoimmune Therapies Backed By $1B In Cash

Jul 31, 2025, 12:01 AM EDT - 7 months ago

Janux: A High-Risk/High-Reward Bet On Oncology And Autoimmune Therapies Backed By $1B In Cash

Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day

Jul 24, 2025, 4:05 PM EDT - 7 months ago

Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day

Janux Therapeutics to Host Virtual R&D Day on July 24, 2025

Jul 17, 2025, 4:30 PM EDT - 7 months ago

Janux Therapeutics to Host Virtual R&D Day on July 24, 2025

Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer

May 15, 2025, 8:00 AM EDT - 10 months ago

Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer

Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

May 8, 2025, 4:01 PM EDT - 10 months ago

Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates

May 5, 2025, 8:30 AM EDT - 10 months ago

Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates

Janux Therapeutics: Buying For The Promising Pipeline, Holding For The Buyout

Apr 5, 2025, 8:14 AM EDT - 11 months ago

Janux Therapeutics: Buying For The Promising Pipeline, Holding For The Buyout

Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Feb 27, 2025, 4:01 PM EST - 1 year ago

Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer

Jan 24, 2025, 4:01 PM EST - 1 year ago

Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer

Janux Therapeutics: mCRPC TAM And Promising JANX007's Phase 1 Data

Jan 8, 2025, 9:00 AM EST - 1 year ago

Janux Therapeutics: mCRPC TAM And Promising JANX007's Phase 1 Data

Best-Performing Stocks Of 2024

Jan 2, 2025, 11:46 PM EST - 1 year ago

Best-Performing Stocks Of 2024

APP BYRN CADL DAVE INOD LUNR MSTR

Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million

Dec 6, 2024, 7:43 PM EST - 1 year ago

Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million

Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Dec 4, 2024, 11:12 PM EST - 1 year ago

Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Janux Therapeutics Announces Proposed Public Offering

Dec 3, 2024, 4:01 PM EST - 1 year ago

Janux Therapeutics Announces Proposed Public Offering

Janux Therapeutics' Prostate Cancer Trial Data Exceeds Investor Expectations: Analyst

Dec 3, 2024, 10:49 AM EST - 1 year ago

Janux Therapeutics' Prostate Cancer Trial Data Exceeds Investor Expectations: Analyst

Janux Therapeutics Stock Soars 70% on Prostate Cancer Drug Trial Results

Dec 3, 2024, 10:39 AM EST - 1 year ago

Janux Therapeutics Stock Soars 70% on Prostate Cancer Drug Trial Results

Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC

Dec 2, 2024, 4:30 PM EST - 1 year ago

Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC

Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion Studies

Nov 25, 2024, 9:00 AM EST - 1 year ago

Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion Studies

Janux Therapeutics: Believable Theory, Strong Early Data, Needs Confirmation

Nov 19, 2024, 1:23 AM EST - 1 year ago

Janux Therapeutics: Believable Theory, Strong Early Data, Needs Confirmation

Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

Nov 6, 2024, 4:01 PM EST - 1 year ago

Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

Aug 7, 2024, 4:01 PM EDT - 1 year ago

Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

Janux Therapeutics Announces Updates to Board of Directors

Jul 22, 2024, 4:01 PM EDT - 1 year ago

Janux Therapeutics Announces Updates to Board of Directors

Janux Therapeutics: Promising T-Cell Engager Platform In Cancer Therapy

Jun 26, 2024, 8:32 AM EDT - 1 year ago

Janux Therapeutics: Promising T-Cell Engager Platform In Cancer Therapy

Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

May 7, 2024, 4:01 PM EDT - 1 year ago

Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

Janux Therapeutics (JANX) stock has gone parabolic: what next?

Apr 30, 2024, 12:06 AM EDT - 1 year ago

Janux Therapeutics (JANX) stock has gone parabolic: what next?

Janux Therapeutics: A Prime Target In Cancer Care's M&A Game

Apr 11, 2024, 9:00 AM EDT - 2 years ago

Janux Therapeutics: A Prime Target In Cancer Care's M&A Game

VKTX, JANX and these biotech stocks are surging in 2024

Apr 2, 2024, 2:10 AM EDT - 2 years ago

VKTX, JANX and these biotech stocks are surging in 2024

ARQT VKTX AMLX MCRB RAPT RVNC

Cancer-Focused Janux Therapeutics Platform Has 'Tremendous Opportunity': Analyst - Janux Therapeutics (NASDAQ:JANX)

Mar 20, 2024, 1:44 PM EDT - 2 years ago

Cancer-Focused Janux Therapeutics Platform Has 'Tremendous Opportunity': Analyst - Janux Therapeutics (NASDAQ:JANX)

Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Mar 8, 2024, 4:01 PM EST - 2 years ago

Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Feb 29, 2024, 1:22 AM EST - 2 years ago

Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Janux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024

Feb 27, 2024, 5:15 PM EST - 2 years ago

Janux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024

Janux Therapeutics Announces Proposed Public Offering of Common Stock

Feb 27, 2024, 5:00 PM EST - 2 years ago

Janux Therapeutics Announces Proposed Public Offering of Common Stock

Janux Therapeutics surges as trial data for prostate cancer therapy shows promise

Feb 27, 2024, 8:38 AM EST - 2 years ago

Janux Therapeutics surges as trial data for prostate cancer therapy shows promise

Janux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors

Feb 26, 2024, 4:05 PM EST - 2 years ago

Janux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors

forprofit12
forprofit12 Feb. 25 at 6:06 PM
$JANX when is ER? Website does not have anything under events.
1 · Reply
bc4
bc4 Feb. 25 at 3:03 PM
$JANX 1 more day to go. Partnership we have with bristol will deliver only good news tomorrow
0 · Reply
civickid75
civickid75 Feb. 24 at 7:15 PM
$JANX the squeeze, if it happens, will take this a lot higher. 13 days to cover. Let’s see if people will take notice.
0 · Reply
Harry900
Harry900 Feb. 24 at 2:55 PM
$JANX Down market, posts are so so fearful and now we’re firming. I’ve been wrong before, but I sense something’s up. I’m calling the basing complete here. Blue skys ahead. GLTA Harry
0 · Reply
metalcook
metalcook Feb. 24 at 2:51 PM
$VIR highest short % of the year. Ofcourse thsi will squeeze. +30% just adds the cash. Now add the value of Astellas as partner + viable drug + viable platform with 2 targets to go + Hep D franshise worth around 600mil$. $JANX at its peak was 2.5bl $ worth. That would equit to 20$ per share for $VIR
0 · Reply
metalcook
metalcook Feb. 23 at 11:29 PM
$VIR $JANX far exceeded expectations. I am not a fan of partnering such an asset. They should go for it alone
0 · Reply
UgoGreg
UgoGreg Feb. 21 at 4:19 PM
$JANX https://youtu.be/ygBN8MilTyc
0 · Reply
bohrsmodel
bohrsmodel Feb. 20 at 9:18 PM
$JANX $50 price target! https://finviz.com/news/315826/where-is-janux-therapeutics-janx-headed-according-to-analysts
0 · Reply
DanishViking92
DanishViking92 Feb. 20 at 8:45 PM
$JANX Maybe we will see a rebound on earnings release if they bring a positive update on the $50M payment they are waiting for.. should i buy or is it too risky? I mean it have been below $10 before.
0 · Reply
Milanfinest
Milanfinest Feb. 19 at 5:26 PM
$JANX so
0 · Reply
Suhair1977
Suhair1977 Feb. 18 at 12:00 PM
$JANX Dead $$ here . Don’t expect much from them
0 · Reply
themojoe
themojoe Feb. 17 at 12:19 PM
$JANX https://investors.januxrx.com/investor-media/news/news-details/2026/Janux-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-Study-of-JANX011/default.aspx
0 · Reply
J7263
J7263 Feb. 17 at 5:12 AM
$JANX another biotech sandtrap.
0 · Reply
MarketWarfare
MarketWarfare Feb. 13 at 9:08 PM
$JANX big money is doing everything possible to steal your shares from you. It's actually blatantly obvious at this point. CEO is an inept shitstain letting it happen.
0 · Reply
ilestz
ilestz Feb. 13 at 6:48 PM
$JANX short interest at 25% thats cool. love to see this still trading 200M below cash. everything is fine
0 · Reply
Jangs
Jangs Feb. 13 at 5:31 PM
$JANX sold half my position today. If it falls back to 13 i buy it back to avg down decently. Im going to get my money back from this mfer one way or another.
1 · Reply
Kevinb511
Kevinb511 Feb. 13 at 2:47 PM
$JANX out of this for a loss. Shocked that this never bounced back
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 13 at 3:43 AM
$JANX RSI: 31.90, MACD: -0.6265 Vol: 0.72, MA20: 13.69, MA50: 14.26 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
MarketWarfare
MarketWarfare Feb. 11 at 2:53 PM
$JANX shorts are going to bring this under 10 and the CEO will just let it happen. It's blatantly obvious at this point.
0 · Reply
ilestz
ilestz Feb. 10 at 9:04 PM
$JANX guess everyone is waiting until feb 26 huh
1 · Reply
Jangs
Jangs Feb. 10 at 8:56 PM
$JANX I cant begin to tell you how much i hate this stock.
0 · Reply
Captenotwo
Captenotwo Feb. 9 at 8:32 PM
$JANX this thing is killing me for more then one reason. A. I’m invested and would like an update of the safety and efficiency B. More importantly my wife has stage 4 mcrc with the kras wt mutations they are targeting. Lfg with some news. Just a little frustrating Cap
2 · Reply